Mirabegron Granted Priority Review for Neurogenic Detrusor Overactivity
The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.
Diagnosis & Disease Information
Gemtesa Approved for Overactive Bladder Treatment
The approval was based on data from the pivotal phase 3 EMPOWUR study.
Overactive Bladder Symptoms Often Remain After Surgery for Severe Prolapse
In a study, approximately half of patients did not experience resolution of overactive bladder symptoms after anterior prolapse repair surgery.
Alpha Blockers May Not Improve Female Lower Urinary Tract Symptoms
The role of alpha adrenergic blockers in the treatment of urinary dysfunction and associated symptoms in women remains unclear.
Study Identifies Predictors of OnabotulinumtoxinA Therapy Continuation
In a study, only 39% of patients with overactive bladder continued BTX therapy for more than 5 years.
Urinary Symptom Severity Affects Adherence to Diuretic Treatment
Adherence to diuretic therapy decreases as lower urinary tract symptoms increase in severity, according to a new study.
Anticholinergics Linked to Increased Dementia Risk
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
Tooth Loss Associated With Overactive Bladder
In a study, patients with chronic periodontitis and overactive bladder (OAB) had significantly fewer teeth (12.8 vs 21.5) compared with patients who did not have OAB.
Vibegron for Overactive Bladder Improves Quality of Life
At 52 weeks, 71.1% of patients treated with vibegron experienced at least a 50% decline in total incontinence episodes from baseline.
Implantable Tibial Neurostimulator Promising for Urge Urinary Incontinence
In a pilot study, the eCoin device yielded a dry rate of 30.33% at 36 weeks.
- Loading...
Loading...
Next post in Overactive Bladder (OAB)
Loading... 
Loading...